CoLucid Pharmaceuticals Announces Initiation of Phase 3 Long-Term, Open-Label Trial of Lasmiditan in Migraine
October 08, 2015 at 08:02 AM EDT
CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product ...